Back to Search

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma

  • Protocol Number: 201911172
  • Principal Investigator: Davis, Andrew
  • Cancer Types: Early Phase

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions